Oral administration of Ki16198 (1 mg in 500 μl for 28 days) significantly reduces metastasis activity in treated mice, showing a notable decrease in metastatic spread to the liver, lungs, and brain. This highlights Ki16198's broad therapeutic potential in mitigating metastasis across multiple organ systems^[1].

In vitro experiments reveal that Ki16198, across a concentration range of 0 to 10 μM over 48 hours, effectively curtails migration and invasion responses to LPA in a manner comparable to Ki16425. Specifically, Ki16198 impacts the invasion response to LPA, without affecting responses to EGF, across various pancreatic cancer cell lines such as Panc-1, CFPAC-1, and BxPC-3^[1].

At a concentration of 10 μM over 48 hours, Ki16198 markedly reduces both the protein and mRNA expression levels of proMMP-9 in YAPC-PD cells, indicating its role in modulating enzymes involved in cancer progression^[1].